A Phase 2 interventional study of HM11260C and Placebo in Obesity, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-09.
Sponsored by Hanmi Pharmaceutical Company Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the optimal dose and regimen of HM11260C, in combination with a hypocaloric diet, to reduce weight in obese subjects who are otherwise considered in stable health.
Phase 2 study
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
This study's enrollment of 297 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Browse Obesity studies →Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age: 18 years to 65 years
Pregnant or nursing (lactating) women
HM11260C 4 mg weekly sc injection
Biological: HM11260C
Placebo weekly sc injection
Biological: Placebo
HM11260C 6 mg weekly sc injection
Biological: HM11260C
HM11260C 6 mg biweekly sc injection
Biological: HM11260C
HM11260C 8 mg biweekly sc injection
Biological: HM11260C
Glucagon-like peptide-1 analogue
Change from baseline in body weight at 20 weeks
Time frame: 20 weeks from baseline
Number of participants with adverse event
Time frame: during 20 weeks of treatment and follow-up period
Change from baseline in HbA1c and fasting plasma glucose level at 20 week
Time frame: 20 weeks from baseline
Change from baseline in blood lipid profile (e.g., cholesterol, and LDL-C level) at 20 week
Cholesterol level, LDL-C level
Time frame: 20 weeks from baseline
Change from baseline in waist circumference at 20 week
Time frame: 20 weeks after baseline
Change from baseline in β-cell function at 20 week
homeostatic model assessment
Time frame: 20 week from baseline
The record gives a start of Feb 2014, a primary completion of Jan 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efpeglenatide
Hanmi Pharmaceutical Company Limited →